Tag Archives: SHPG stock

Bioverativ(BIVV) To Be Acquired By Sanofi(SNY) At Huge 64% Premium

By |
4 Comments

It was just one year ago when Biogen(BIIB) spun off hemophilia and blood disorder specialist Bioverativ(BIVV). With the stock trading in the 40s post-spin, we highlighted some disparate analyst opinions of the spin. The most bullish, Gabelli & Company, has a price target of $58 for Bioverativ stock.  This past Friday, Bioverativ stock closed at $64.11, above Gabelli’s… Read More »

Short Attention Spin- Shire To Consider Spinning Off Neurological Division

By |
7 Comments

Shire Pharmaceuticals (SHPG) announced last week that it will be “assessing strategic options” for its Neuroscience franchise. The move would allow the company to focus its efforts on its rare diseases division. From the company’s Q2 statement: With the acquisition and integration of Baxalta, Shire has solidified its leadership position in rare diseases with an unparalleled inline portfolio, innovative… Read More »